Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis.
For years, artificial-intelligence evangelists have boasted about the technology’s capacity to revolutionize drug development and medical research.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- ASX set to fall, AI stocks rebound on Wall Street theage.com.au
- ASX set to fall, AI stocks rebound on Wall Street smh.com.au
- Wall Street researchers just used Claude to design a drug. The experiment has spawned a new investment thesis. marketwatch.com
- AI rally fades away from Wall Street as a tiny IPO makes big waves cnbc.com
